Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $51.72M rose 5172100.0% year over year, ahead of the +7755.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 23198.2% from the prior quarter. Over 3 fiscal years it compounded at +68.0% a year.

Context

  • Financing cash flow amounted to 140016.7% of revenue in FY2025, up 137842.9 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +5172100.0% holds above the trailing-twelve-month pace of +7755.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$51.72M+23198.2% QoQ
Last fiscal yearDec 2025
$50.41M+3701.4% YoY
LTMMar 2026
$102.13M+7755.9% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5172100.0%——
1 year+3701.4%——
3-year CAGR+68.0%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
50.41M USD
Year-over-year change
+3701.4%
4-year CAGR
-40.5%

Financing Cash Flow vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7755.9% is the 3rd highest of 10, against a peer median of -9.0%.
  • Financing cash flow amounts to 329441.9% of revenue for LYEL, versus a peer median of 28.5%.
LYEL Competitors
Financing Cash Flow for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$173.2M USD+64727.2%-4.7%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$141.48M USD+10580.1%+128.2%—
CABACabaletta Bio, Inc.LTM Mar 2026$126.17M USD+2854.7%+44.9%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$102.13M USD+7755.9%+68.0%329441.9%
EDITEditas Medicine, Inc.LTM Mar 2026$41.91M USD-23.0%+215.9%108.3%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$37.29M USD-71.1%+117.0%—
GNLXGenelux CorporationLTM Mar 2026$18.87M USD-49.5%—235825.0%
AMRNAmarin Corporation plcLTM Mar 2026$2.59M USD+127.8%+75.3%1.2%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.02M CHF-9.0%-10.2%28.5%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$191.89K USD-76.4%-2.7%—
SLNSilence Therapeutics plcLTM Mar 2026$911.01 USD—-93.4%0.1%
Peer median (excluding LYEL) —-9.0%+44.9%28.5%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Depreciation & Amortization13.62M16.47M20.25M19.63M11.54M
Deferred Income Tax39.51M0000
Stock-Based Compensation62.2M047.08M33.14M41.83M
Change in Working Capital4.02M(82.02M)3.42M(3.12M)(9.89M)
Accounts Receivables00000
Inventory00000
Accounts Payables91K667K1.46M(3.23M)(2.34M)
Other Working Capital3.92M(82.68M)1.96M114K(7.56M)
Other Non-Cash Items4.62M79.11M183K130.95M80.95M
Operating Cash Flow(126.25M)(169.56M)(163.69M)(162.39M)(150.02M)
Capital Expenditures(65.5M)(24.28M)(2.69M)(464K)(780K)
Acquisitions (Net)673.47M00(31.35M)(41.2M)
Purchases of Investments(673.47M)(406.32M)(476.88M)(394.71M)(259.71M)
Sales of Investments617.4M419.05M663.61M548.94M374.68M
Other Investing Activities(673.47M)000(18.9M)
Investing Cash Flow(121.57M)(11.54M)184.05M122.42M54.1M
Debt Repayment00000
Common Stock Issued391.8M11.1M2.2M1.4M50.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.44M(461K)(457K)(76K)(1K)
Financing Cash Flow401.24M10.64M1.74M1.33M50.41M
Effect of Forex Changes0186K(4K)00
Net Change in Cash153.42M(170.27M)22.09M(38.64M)(45.52M)
Free Cash Flow(191.75M)(193.83M)(166.38M)(162.86M)(150.8M)

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.